ArticleVeterinary ophthalmology2025
Retrospective Assessment of Carbonic Anhydrase Inhibitors in Topical or Episcleral Implant Form for the Treatment of Equine Glaucoma.
Article in Veterinary ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo assess whether topical carbonic anhydrase inhibitors (CAIs) with or without episcleral brinzolamide implants control intraocular pressure (IOP) in horses with glaucoma. ANIMALS STUDIED: 12 client-owned horses diagnosed with glaucoma. PROCEDURES: Medical records of horses treated with topical CAIs for ≥ 14 days, with a subset receiving episcleral brinzolamide implants, were reviewed. Diagnosis, signalment, concurrent ocular disease, medications, IOP, visual status, and additional procedures were recorded. Treatment failure was defined as horses with IOP > 30 mmHg resulting in phthisis bulbi or requiring a procedure or enucleation.
resultsSecondary glaucoma was diagnosed in 8/12 (67%) eyes and primary glaucoma in 4/12 (33%) eyes. IOP was < 30 mmHg in 7/12 (58%) eyes after treatment with topical CAIs for a median of 28 days. Episcleral brinzolamide implants were placed in 7/12 eyes after a median of 58 days of medical therapy. Treatment failure occurred in 3/7 horses (43%) receiving brinzolamide implants at a median of 189 days and in 4/5 medical therapy-only horses (80%) at a median of 51 days. While 6/12 eyes (50%) were visual at last follow-up (median of 161 days), enucleation was the final outcome in 10/12 (83%) eyes.
conclusionsTopical CAIs appear to result in temporary IOP control in a subset of horses, though some horses may be refractory. Episcleral brinzolamide implants may extend IOP control in horses with glaucoma, but prognosis for vision remains guarded and further optimization is needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.